AspenBio Pharma

AppyScore™
for Acute Appendicitis Management

  • Home
  • About Us
    • Management Team
    • Board of Directors
  • About Appendicitis
  • AppyScore™ Solution
  • Investor Relations
    • Press Releases
    • News Sign Up
    • Stock Quote & Charts
    • SEC Filings
    • Committees
    • Corporate Governance
    • Professional Advisors
    • FDA Radiation Initiative – Feb ‘10FDA Radiation Initiative – Feb ‘10
    • Investor PresentationInvestor Presentation
    • Shareholder Letter Apr. 2011Shareholder Letter Apr. 2011
  • Careers
  • Contact Us
  • Press Releases
  • News Sign Up
  • Stock Quote & Charts
  • SEC Filings
  • Committees
  • Corporate Governance
  • Professional Advisors
  • FDA Radiation Initiative – Feb ‘10FDA Radiation Initiative – Feb ‘10
  • Investor PresentationInvestor Presentation
  • Shareholder Letter Apr. 2011Shareholder Letter Apr. 2011

Professional Advisors

Legal Counsel, General

Ballard Spahr, L.L.P.

Philadelphia, PA

Legal Counsel, Intellectual Property

Greenlee Sullivan, P.C.

Boulder, CO

Auditors

GHP Horwath, P.C.

Denver, CO

Investor Relations

Liolios Group Investor Relations, CA

Contact: 949-574-3860

<back / top

© 2011 AspenBio Pharma, Inc | 1585 South Perry Street | Castle Rock, CO 80104 | Phone: 303-794-2000 | Fax: 303-798-8332

  • Home
  • About Us
  • About Appendicitis
  • AppyScore™ Solution
  • Investor Relations
  • Careers
  • Contact Us

Certain statements made in this presentation include historical information and forward looking actions that AspenBio Pharma anticipates based on certain assumptions. These statements are indicated by words such as "expect", "anticipate", "should" and similar words are indicating uncertainty in facts, figures and outcomes. While AspenBio Pharma believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such statements will prove to be correct. The risks associated with the company are detailed in the Company's Annual Report, as amended on Form 10-K for the year ended December 31, 2010 and other reports filed by the Company with the Securities and Exchange Commission.